menu
    • menu

    Company profile for HepaRegeniX

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases. The laboratory of Prof. Lars Zender identified Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) as a key regulator of liver regeneration. Suppression of MKK4 gene expression by small RNA molecules unlocks the regenerative capacity of hepatocytes even in severely diseased livers. These findings paved the way for the unique an...
    HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases. The laboratory of Prof. Lars Zender identified Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) as a key regulator of liver regeneration. Suppression of MKK4 gene expression by small RNA molecules unlocks the regenerative capacity of hepatocytes even in severely diseased livers. These findings paved the way for the unique and promising therapeutic concept to develop small molecule MKK4 inhibitors to treat acute and chronic liver diseases. In particular, following thorough characterization of the underlying molecular mechanism of drug.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HepaRegeniXGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Alfred-Mendler-Weg 25/1, 89075 Ulm
    Telephone
    Telephone
    +49 (0)7071 6396731
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.heparegenix.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HepaRegeniX Completes Phase Ib HRX-215 Liver Study
    HepaRegeniX Completes Phase Ib HRX-215 Liver Study

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236026/0/en/HepaRegeniX-Completes-Phase-Ib-Study-of-HRX-215-to-Enhance-Liver-Regeneration-in-Patients-Undergoing-Minor-Liver-Resection.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    HepaRegeniX Doses First Patient in Phase Ib Trial with HRX-215
    HepaRegeniX Doses First Patient in Phase Ib Trial with HRX-215

    10 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/10/3096394/0/en/HepaRegeniX-Doses-First-Patient-in-Phase-Ib-Trial-with-Small-Molecule-Inhibitor-HRX-215-to-Promote-Liver-Regeneration.html

    GLOBENEWSWIRE
    10 Jun 2025
    Share Share
    HepaRegeniX Founder Presents HRX-215 Data at EASL Congress 2025
    HepaRegeniX Founder Presents HRX-215 Data at EASL Congress 2025

    08 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/08/3077246/0/en/HepaRegeniX-Scientific-Founder-Covers-HRX-215-Development-and-Clincial-Data-in-Plenary-at-the-European-Association-for-the-Study-of-the-Liver-Congress-2025.html

    GLOBENEWSWIRE
    08 May 2025
    Share Share
    HepaRegeniX secures €21.5M for HRX-215 liver regeneration
    HepaRegeniX secures €21.5M for HRX-215 liver regeneration

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061487/0/en/HepaRegeniX-completes-21-5-million-financing-to-support-clinical-advancement-of-HRX-215-for-liver-regeneration.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    HepaRegeniX Raises €15M For HRX-215 Liver Regeneration Development
    HepaRegeniX Raises €15M For HRX-215 Liver Regeneration Development

    10 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/10/2910869/0/en/HepaRegeniX-raises-15-million-Series-C-round-to-advance-clinical-development-of-HRX-215-for-liver-regeneration.html

    GLOBENEWSWIRE
    10 Jul 2024
    Share Share
    HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215
    HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215

    14 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/14/2846504/0/en/HepaRegeniX-publishes-data-for-its-first-in-class-MKK4-inhibitor-HRX-215-for-the-treatment-of-acute-and-chronic-liver-diseases-in-Cell.html

    GLOBENEWSWIRE
    14 Mar 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search